drugset / Trial / NCT05874167

A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

NCT05874167

Phase 1 Completed 50 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6013 and each component in healthy adult volunteers in fast condition.

Timeline

Start
2022-08-08
Primary completion
2022-10-11
Completion
2022-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule Oral
Subject Metformin Small molecule Oral

Indications

No indication recorded.